What is Clarus Therapeutics Holdings Current Ratio?
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Clarus Therapeutics Holdings's current ratio for the quarter that ended in Jun. 2022 was 0.79.
Clarus Therapeutics Holdings has a current ratio of 0.79. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Clarus Therapeutics Holdings has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Clarus Therapeutics Holdings's Current Ratio or its related term are showing as below:
CRXTQ's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.88 * Ranked among companies with meaningful Current Ratio only.
Clarus Therapeutics Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clarus Therapeutics Holdings's Current Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarus Therapeutics Holdings's Current Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Clarus Therapeutics Holdings's Current Ratio falls into.
Clarus Therapeutics Holdings Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarus Therapeutics Holdings (OTCPK:CRXTQ) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Clarus Therapeutics Holdings Current Ratio Related Terms
Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRXTQ has been successfully added to your